Physician profile
Daniel Baram
NPI 1407881345
$4,956.73
in general payments reported to CMS, 2019-2025
14 companies · $119 in 2025
The $119 reported for 2025 was less than what a typical Critical Care Medicine (Internal Medicine) provider received nationally (typical 2025 total: $189).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,124 · 2020: $358 · 2021: $591 · 2022: $1,165 · 2023: $868 · 2024: $732 · 2025: $119.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,719.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,719.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,051.65 | 2019-2024 | Fasenra, Tezspire, Airsupra |
| Ethicon INC. | $724.68 | 2020-2022 | |
| Genzyme Corporation | $660.41 | 2019-2025 | |
| Insmed, INC. | $536.86 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.44 | 2019-2024 | Ofev |
| Glaxosmithkline, LLC. | $421.19 | 2022-2024 | Nucala, Trelegy Ellipta, Arexvy |
| United Therapeutics Corporation | $297.83 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $246.78 | 2019 | |
| Mylan Specialty L.P. | $220.08 | 2020-2023 | Yupelri |
| Grifols USA, LLC | $159.77 | 2022-2023 | Prolastin-C Liquid |
| Inspire Medical Systems, INC. | $117.16 | 2019 | |
| Covidien Lp | $25.11 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.96 | 2025 | Glassia |
| Amgen INC. | $21.81 | 2023 | Tezspire |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Baram listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.